Az onkológiai gyógyszerekre fordított éves egészségbiztosítási kiadások meghatározása magyarországon

Translated title of the contribution: Assessment of annual health insurance reimbursement of oncology drugs in Hungary

I. Boncz, Éva Donkáné Verebes, Ferenc Oberfrank, M. Kásler

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of our study is to analyse the health insurance reimbursement of oncology drugs in outpatient care, inpatient care and named patient system. Data were derived from the database of the National Health Insurance Fund Administration (OEP). The analysis covers data of pharmaceuticals with health insurance reimbursement between 1 January and 31 December, 2008. We performed the analysis according to the ATC group "L" and ICD codes C00-C99 and D00-D48. Within "L" ATC group, for ICD codes C00-C99 and D00-D48 the annual health insurance expenditure for outpatient and named patient drugs were 36.3 billion Hungarian Forints (HUF) (144.5 million EUR, 211.3 million USD). For drugs used in the acute inpatient care, we found 22.59 billion HUF (89.9 million EUR, 131.5 million USD) annual health insurance expenditure. The Hungarian National Health Insurance Fund Administration (OEP) spent altogether 58.9 billion HUF (234.4 million EUR, 342.8 million USD) for the reimbursement of oncological drugs in outpatient, named patient and inpatient care. The reimbursement of oncological drugs represents a significant expenditure for the Hungarian National Health Insurance Fund Administration (OEP).

Original languageHungarian
Pages (from-to)283-288
Number of pages6
JournalMagyar Onkologia
Volume54
Issue number4
DOIs
Publication statusPublished - Dec 1 2010

Fingerprint

Health Insurance Reimbursement
Hungary
National Health Programs
Health Expenditures
Pharmaceutical Preparations
Inpatients
International Classification of Diseases
Health Insurance
Patient Care
Outpatients
Ambulatory Care
Databases

ASJC Scopus subject areas

  • Oncology

Cite this

Az onkológiai gyógyszerekre fordított éves egészségbiztosítási kiadások meghatározása magyarországon. / Boncz, I.; Donkáné Verebes, Éva; Oberfrank, Ferenc; Kásler, M.

In: Magyar Onkologia, Vol. 54, No. 4, 01.12.2010, p. 283-288.

Research output: Contribution to journalArticle

@article{46d1c47315f84e7fa76d4fef5b64bf29,
title = "Az onkol{\'o}giai gy{\'o}gyszerekre ford{\'i}tott {\'e}ves eg{\'e}szs{\'e}gbiztos{\'i}t{\'a}si kiad{\'a}sok meghat{\'a}roz{\'a}sa magyarorsz{\'a}gon",
abstract = "The aim of our study is to analyse the health insurance reimbursement of oncology drugs in outpatient care, inpatient care and named patient system. Data were derived from the database of the National Health Insurance Fund Administration (OEP). The analysis covers data of pharmaceuticals with health insurance reimbursement between 1 January and 31 December, 2008. We performed the analysis according to the ATC group {"}L{"} and ICD codes C00-C99 and D00-D48. Within {"}L{"} ATC group, for ICD codes C00-C99 and D00-D48 the annual health insurance expenditure for outpatient and named patient drugs were 36.3 billion Hungarian Forints (HUF) (144.5 million EUR, 211.3 million USD). For drugs used in the acute inpatient care, we found 22.59 billion HUF (89.9 million EUR, 131.5 million USD) annual health insurance expenditure. The Hungarian National Health Insurance Fund Administration (OEP) spent altogether 58.9 billion HUF (234.4 million EUR, 342.8 million USD) for the reimbursement of oncological drugs in outpatient, named patient and inpatient care. The reimbursement of oncological drugs represents a significant expenditure for the Hungarian National Health Insurance Fund Administration (OEP).",
keywords = "drug expenditures, health insurance, health policy, oncology",
author = "I. Boncz and {Donk{\'a}n{\'e} Verebes}, {\'E}va and Ferenc Oberfrank and M. K{\'a}sler",
year = "2010",
month = "12",
day = "1",
doi = "10.1556/MOnkol.54.2010.4.2",
language = "Hungarian",
volume = "54",
pages = "283--288",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - Az onkológiai gyógyszerekre fordított éves egészségbiztosítási kiadások meghatározása magyarországon

AU - Boncz, I.

AU - Donkáné Verebes, Éva

AU - Oberfrank, Ferenc

AU - Kásler, M.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - The aim of our study is to analyse the health insurance reimbursement of oncology drugs in outpatient care, inpatient care and named patient system. Data were derived from the database of the National Health Insurance Fund Administration (OEP). The analysis covers data of pharmaceuticals with health insurance reimbursement between 1 January and 31 December, 2008. We performed the analysis according to the ATC group "L" and ICD codes C00-C99 and D00-D48. Within "L" ATC group, for ICD codes C00-C99 and D00-D48 the annual health insurance expenditure for outpatient and named patient drugs were 36.3 billion Hungarian Forints (HUF) (144.5 million EUR, 211.3 million USD). For drugs used in the acute inpatient care, we found 22.59 billion HUF (89.9 million EUR, 131.5 million USD) annual health insurance expenditure. The Hungarian National Health Insurance Fund Administration (OEP) spent altogether 58.9 billion HUF (234.4 million EUR, 342.8 million USD) for the reimbursement of oncological drugs in outpatient, named patient and inpatient care. The reimbursement of oncological drugs represents a significant expenditure for the Hungarian National Health Insurance Fund Administration (OEP).

AB - The aim of our study is to analyse the health insurance reimbursement of oncology drugs in outpatient care, inpatient care and named patient system. Data were derived from the database of the National Health Insurance Fund Administration (OEP). The analysis covers data of pharmaceuticals with health insurance reimbursement between 1 January and 31 December, 2008. We performed the analysis according to the ATC group "L" and ICD codes C00-C99 and D00-D48. Within "L" ATC group, for ICD codes C00-C99 and D00-D48 the annual health insurance expenditure for outpatient and named patient drugs were 36.3 billion Hungarian Forints (HUF) (144.5 million EUR, 211.3 million USD). For drugs used in the acute inpatient care, we found 22.59 billion HUF (89.9 million EUR, 131.5 million USD) annual health insurance expenditure. The Hungarian National Health Insurance Fund Administration (OEP) spent altogether 58.9 billion HUF (234.4 million EUR, 342.8 million USD) for the reimbursement of oncological drugs in outpatient, named patient and inpatient care. The reimbursement of oncological drugs represents a significant expenditure for the Hungarian National Health Insurance Fund Administration (OEP).

KW - drug expenditures

KW - health insurance

KW - health policy

KW - oncology

UR - http://www.scopus.com/inward/record.url?scp=79951995846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951995846&partnerID=8YFLogxK

U2 - 10.1556/MOnkol.54.2010.4.2

DO - 10.1556/MOnkol.54.2010.4.2

M3 - Article

VL - 54

SP - 283

EP - 288

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 4

ER -